Video Interview - Johnson & Johnson’s approach to external innovation

An all-inclusive life science conference

Save the date for next yearJanuary 12–14, 2026 | San Francisco, CA

Video Interview - Johnson & Johnson’s approach to external innovation

By EBD GroupShare

William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.

Click here or above to learn about how partners complement J&J innovation, how digital health, artificial intelligence and machine learning fit into their strategy, and the details regarding the company’s presence in China over the past 50 years.

Drug Development

Innovation

Biotech

ChinaBio Partnering Forum 2020

Related news

Drug Development

Biopharma Partnering and Financing Trends, H1 2020

With the help of Biomedtracker, analysts at Pharma Intelligence have taken a deep dive into the worldwide biopharma industry partnership and financial dealmaking during the first halves of 2019 and 2020. What they found is astounding and inside the new white paper.

Drug Development

Biotech Startups: How to Succeed in a COVID-19 World

Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.

Interview: Promoting prosperity in the life science sectors of China and the UK

In this exclusive interview, Her Majesty’s Trade Commissioner for China at the Department for International Trade, John Edwards, discusses how China’s healthcare and life sciences markets are growing rapidly and are driven by increased demand and changes to regulations, plus much more.

Drug Development

Interview: Importance of diversity and partnering in global life sciences

ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.